The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
May 16th 2025
Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.
First New Antiviral for Influenza in 2 Decades Approved by FDA
October 24th 2018Officials with the FDA have approved baloxavir marboxil (Xofluza, Shionogi) for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours.
Read More
Pharmacy Times Continuing Educational Activity: Demystifying Medical Cannabis
October 24th 2018Panelists will discuss and collaboratively provide an overview of medical cannabis, identify the therapeutic role of cannabis, examine the regulation of medical cannabis and establish the role of health care providers in prescribing medical cannabis.
Read More
Generic Clobazam Tablets Granted FDA Approval
October 24th 2018Breckenridge Pharmaceutical's Clobazam Tablets, CIV, generic for Onfi® Tablets (Lundbeck), has been granted FDA approval for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older.
Read More
A New Safe Medication Disposal Option is Coming to Walgreens Pharmacies
October 24th 2018Beginning in spring 2019, all Walgreens pharmacies that do not offer a safe medication disposal kiosk will stock a take home safe medication disposal kit in the pharmacy that will be available at no cost upon patient request.
Read More
Global Operation Targets Illegal Drug Sales on Web
October 23rd 2018To target the infrastructure supporting the illegal online sales of drugs, a series of recent OCI cybercrime investigations focused on credit card processors involved in an arrangement known as “transaction laundering” or “factoring.”
Read More
FDA Approves Dupilumab as Additional Maintenance Therapy in Certain Children with Asthma
October 22nd 2018The FDA has approved dupilumab (Dupixent®, Regeneron and Sanofi) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
Read More
Broadly Neutralizing Antibodies Combination May Suppress HIV Without Antiretroviral Therapy
October 19th 2018A combination of next generation broadly neutralizing antibodies might be able to achieve long-term viral suppression of HIV without the need for a daily antiretroviral pill, according to recently published research.
Read More
Positive Topline Results Shown for Dupilumab in Phase 3 Trials in Patients with CRSwNP
October 17th 2018A pair of pivotal Phase 3 placebo-controlled trials that evaluated dupilumab (Dupixent, Sanofi and Regeneron) for adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all primary and secondary endpoints.
Read More
Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation Granted FDA Approval
October 16th 2018Talazoparib, a poly ADP-ribose polymerase (PARP) inhibitor, is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer who are selected for the therapy based on an FDA-approved companion diagnostic.
Read More
CMS Officials Propose Requiring Drug Manufacturers to Disclose Drug Prices in TV Ads
October 16th 2018Officials with the Pharmaceutical Research and Manufacturing Association (PhRMA) said in a press release that they plan to request member companies’ direct-to-consumer (DTC) television advertisements to direct patients to information about medicine costs, including the list price of the medicine, out-of-pocket costs or other context about the potential cost of the medicine and available financial assistance.
Read More